前列腺癌激素治疗

预约门诊
打印

科室与专家门诊

妙佑医疗国际是美国规模最大、经验最丰富的医疗机构之一，在亚利桑那州、佛罗里达州和明尼苏达州都设有院区。我们的工作人员涉及数十种专业，通过齐心协力确保高品质治疗与成功康复。

有相关专长的科室

研究此手术的领域

行此手术的医生

编辑搜索过滤条件
close

缩小搜索范围

  1. 未找到姓氏以该字母开头的医生 A
  2. 未找到姓氏以该字母开头的医生 B
  3. 查找姓氏以该字母开头的医生 C
  4. 未找到姓氏以该字母开头的医生 D
  5. 未找到姓氏以该字母开头的医生 E
  6. 未找到姓氏以该字母开头的医生 F
  7. 未找到姓氏以该字母开头的医生 G
  8. 未找到姓氏以该字母开头的医生 H
  9. 未找到姓氏以该字母开头的医生 I
  10. 未找到姓氏以该字母开头的医生 J
  11. 未找到姓氏以该字母开头的医生 K
  12. 未找到姓氏以该字母开头的医生 L
  13. 未找到姓氏以该字母开头的医生 M
  14. 未找到姓氏以该字母开头的医生 N
  15. 未找到姓氏以该字母开头的医生 O
  16. 未找到姓氏以该字母开头的医生 P
  17. 未找到姓氏以该字母开头的医生 Q
  18. 未找到姓氏以该字母开头的医生 R
  19. 未找到姓氏以该字母开头的医生 S
  20. 未找到姓氏以该字母开头的医生 T
  21. 未找到姓氏以该字母开头的医生 U
  22. 未找到姓氏以该字母开头的医生 V
  23. 未找到姓氏以该字母开头的医生 W
  24. 未找到姓氏以该字母开头的医生 X
  25. 未找到姓氏以该字母开头的医生 Y
  26. 未找到姓氏以该字母开头的医生 Z
重置所有过滤器

显示$起始范围 - $结束范围/源自可用$可用医生

  1. Ruqin Chen, M.D., M.B.

    Ruqin Chen, M.D., M.B.

    1. Oncologist
    1. Jacksonville, FL
    擅长领域：

    Chemotherapy, Immunotherapy, Targeted drug therapy, Hormone therapy for prostate cancer, Chemotherapy for prostate canc...er, BCG treatment for bladder cancer, Prostate cancer, Bladder cancer, Kidney cancer, Melanoma, Metastatic bladder cancer, Recurrent bladder cancer

研究

凭借先进的实验室空间以及肿瘤科、泌尿科和妙佑医疗国际的顶尖医生研究员，我们致力于为前列腺癌等泌尿系统癌症患者改进治疗方案。我们与患者携手合作，提供针对这类癌症的最佳护理。我们开展研究，以更好地理解癌症生物学，并探索通过手术和非手术方法更好地靶向癌细胞的方法。妙佑医疗国际还持续开展临床试验，探索减少激素治疗用药量并应对激素治疗在部分前列腺癌患者中引发副作用的方法。

前列腺癌研究系与妙佑医疗国际综合癌症中心合作开展。妙佑医疗国际综合癌症中心接受美国国家癌症研究所的资助，是指定的综合癌症中心。这是对该中心在癌症预防、诊断和治疗方面的卓越科学成就和多学科资源的认可。

著述

请参阅美国国家医学图书馆检索服务系统 PubMed 所收录的妙佑医疗国际医生在前列腺癌激素治疗领域的著述目录。

Research Profiles

编辑搜索过滤条件
close

缩小搜索范围

查看所有医生 • 所有位置

来自妙佑医疗国际员工

在 Mayo Clinic 治疗

申请预约
关于在 Mayo Clinic 治疗
July 15, 2025
打印
  1. Prostate cancer. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1459. Accessed May 27, 2025.
  2. Prostate cancer: Early stage. National Comprehensive Cancer Network. https://www.nccn.org/patientresources/patient-resources/guidelines-for-patients/guidelines-for-patients-details?patientGuidelineId=49. Accessed May 27, 2025.
  3. Lowrance W, et al. Updates to advanced prostate cancer: AUA/SUO guideline (2023). The Journal of Urology. 2023; doi:10.1097/JU.0000000000003452.
  4. Hormone therapy for prostate cancer. National Cancer Institute. https://www.cancer.gov/types/prostate/prostate-hormone-therapy-fact-sheet. Accessed May 27, 2025.
  5. Smith MR. Side effects of androgen deprivation therapy. https://www.uptodate.com/contents/search. Accessed Feb. 16, 2023.
  6. Dmochowski RR, et al., eds. Management of recurrent and newly metastatic prostate cancer. In: Campbell-Walsh-Wein Urology. 13th ed. Elsevier; 2026. https://www.clinicalkey.com. Accessed May 27, 2025.
  7. Hussain M, et al. Metastatic hormone-sensitive prostate cancer and combination treatment outcomes: A review. JAMA Oncology. 2024; doi:10.1001/jamaoncol.2024.0591.
  8. Hamid AA, et al. Metastatic hormone-sensitive prostate cancer: Toward an era of adaptive and personalized treatment. American Society of Clinical Oncology Educational Book. 2023; doi:10.1200/EDBK_390166.
  9. Gudenkauf LM, et al. Balancing hormone therapy: Mitigating adverse effects of androgen-deprivation therapy and exploring alternatives in prostate cancer management. American Society of Clinical Oncology Educational Book. 2024; doi:10.1200/EDBK_433126.
  10. Boue A, et al. Does hormone therapy impact cognition in patients with prostate cancer? A systematic review and meta-analysis. Cancer. 2024; doi:10.1002/cncr.35210.
  11. Solanki AJ, et al. A practical guide for assessing and managing cardiovascular risk during androgen-deprivation therapy in patients with prostate cancer. Cancer. 2024; doi:10.1002/cncr.35285.
  12. Lupron (prescribing information). AbbVie Inc.; 2023. https://www.lupron.com/pi.html. Accessed June 6, 2025.
  13. Zoladex (prescribing information). AstraZeneca Pharmaceuticals LP; 2023. https://www.zoladexhcp.com/dosing-administration/. Accessed June 6, 2025.
  14. Vaz R, et al. Testicular cancer — Surgical treatment. Frontiers in Endocrinology. 2019; doi:10.3389/fendo.2019.00308.
  15. Dawson NA, et al. Overview of the treatment of castration-resistant prostate cancer (CRPC). https://www.uptodate.com/contents/search. Accessed June 12, 2025.
  16. Hormone therapy for prostate cancer. National Cancer Institute. https://www.cancer.gov/types/prostate/prostate-hormone-therapy-fact-sheet. Accessed June 12, 2025.
  17. Harris WP, et al. Androgen deprivation therapy: Progress in understanding mechanisms of resistance and optimizing androgen depletion. Nature Clinical Practice Urology; 2009. doi:10.1038/ncpuro1296.
  18. Cancer stat facts: Prostate cancer. National Cancer Institute. https://seer.cancer.gov/statfacts/html/prost.html. Accessed June 12, 2025.
  19. Harris KM. Allscripts EPSi. Mayo Clinic. April 23, 2024.
  20. Questions to ask about prostate cancer. American Cancer Society. https://www.cancer.org/cancer/types/prostate-cancer/detection-diagnosis-staging/talking-with-doctor.html. Accessed June 18, 2025.
  21. Questions to ask about cancer care. National Comprehensive Cancer Network. https://www.nccn.org/patientresources/patient-resources/resources-for-patients-caregivers/questions-to-ask-about-cancer. Accessed June 18, 2025.
  22. Anheuser P, et al. Complications associated with inguinal orchiectomy and scrotal orchiectomy. Urologe. 2014; doi:10.1007/s00120-014-3487-3.
  23. Hormone therapy for advanced prostate cancer. Mayo Clinic Press. https://mcpress.mayoclinic.org/cancer/hormone-therapy-for-advanced-prostate-cancer. Accessed June 18, 2025.

相关

Mayo Clinic 新闻

产品与服务

妙佑医疗国际明尼苏达州罗切斯特院区在《美国新闻与世界报道》全美最佳泌尿科医院评选中名列前茅。

了解更多关于这一最高荣誉的信息

前列腺癌激素治疗